You are here: Industry Insights > mRNA-1273

News List

Prior SARS-CoV-2 Infection Ups Protection for Vaccinated Drugs
November 16, 2021
For individuals vaccinated with mRNA COVID-19 vaccines, prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a lower risk for breakthrough infection...
SFDA approves Moderna’s Covid-19 vaccine for use in Saudi Arabia pharmaceutical-technology
July 12, 2021
The Saudi Food and Drug Authority (SFDA) has granted approval for the registration of Moderna’s Covid-19 vaccine, mRNA-1273, in the Kingdom of Saudi Arabia.
Covid-19 vaccines show efficacy in adolescents, paving path towards herd immunity pharmaceutical-technology
June 08, 2021
There are globally now more people vaccinated for COVID-19 than confirmed cases of COVID-19. With globally over 400 million people fully vaccinated and over 1.7 billion vaccine doses administered, herd immunity seems achievable.
Moderna’s COVID-19 vaccine 93 percent effective in adolescents europeanpharmaceuticalreview
May 28, 2021
New Phase II/III study data shows Moderna’s COVID-19 vaccine is safe and immunogenic in patients aged 12 to less than 18 years old.
Moderna COVID-19 Vaccine Highly Effective in Children 12 and Older drugs
May 26, 2021
The Moderna COVID-19 vaccine fully protects children aged 12 to 17 years, the company announced Tuesday.
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine prnasia
May 24, 2021
Moderna and Samsung Biologics announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine.
Moderna, Samsung Biologics sign agreement for fill-finish manufacturing of COVID-19 vaccine expresspharma
May 24, 2021
The agreement will further enable global supply of mRNA-1273, Moderna’s COVID-19 vaccine with Samsung Biologics’ fill and finish manufacturing service.
Moderna commences trial of COVID-19 vaccine in children expresspharma
March 17, 2021
The study will assess the safety and effectiveness of two doses of mRNA-1273 given 28 days apart in children aged six months to less than 12 years.
First patients receive Moderna’s modified COVID-19 vaccine candidates europeanpharmaceuticalreview
March 12, 2021
Moderna has begun testing two new mRNA COVID-19 vaccines, one specifically targeting the B.1.351 variant and the other a multivalent candidate.
Moderna’s COVID-19 vaccine is 94 percent effective, according to trial results europeanpharmaceuticalreview
January 05, 2021
Phase III trial data suggests the mRNA-1273 vaccine is safe and highly effective at preventing COVID-19 in adults.

Previous page 1 2 3 4 5 6 Next page